Virtu Financial LLC Aravive, Inc. Transaction History

Virtu Financial LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 26, 2024	SELL	$0.11 - $0.22 $5,771 - $11,542	-52,465 Reduced 58.25%	37,611 $5,000
Q3 2023 Nov 14, 2023	BUY	$0.11 - $1.76 $9,908 - $158,533	90,076 New	90,076 $12,000
Q1 2023 May 01, 2023	BUY	$1.29 - $2.46 $18,372 - $35,035	14,242 New	14,242 $28,000
Q4 2021 Feb 17, 2022	SELL	$2.19 - $4.07 $23,785 - $44,204	-10,861 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$3.67 - $5.8 $39,859 - $62,993	10,861 New	10,861 $40,000
Q2 2021 Sep 17, 2021	SELL	$4.65 - $6.42 $104,871 - $144,790	-22,553 Closed	0 $0
Q1 2021 May 19, 2021	BUY	$5.11 - $9.24 $115,245 - $208,389	22,553 New	22,553 $149,000

28.1K

Ticker ARAV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,518,300
Description
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of pl...

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

Stay updated on Virtu Financial LLC with notifications on news.